1 Stock Under $50 with Exciting Potential and 2 Facing Challenges
Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.
2 Unpopular Stocks That Deserve a Second Chance and 1 We Question
1 Surging Stock Worth Your Attention and 2 We Find Risky
An expert in longevity medicine and preventive healthcare, Vinjamoori joins Hims & Hers to help more men feel great at every stage of life
The acquisition extends the company's leadership position across Australia, Canada, Germany, Japan, and the United Kingdom, with the scale to redefine healthcare for hundreds of millions of people
Building on its Canadian launch and the historic introduction of generic semaglutide, Hims & Hers brings the full power of the world's largest consumer health platform — and Juniper's proven track record...
Closing brings world-class technology and clinical infrastructure to a market where Juniper has helped patients achieve clinically meaningful weight loss